Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…)

Slides:



Advertisements
Similar presentations
ENDEAVOR IV Acronym: ENDEAVOR IV. Lead investigator: Dr Martin Leon from Columbia University, New York Source: Transcatheter cardiovascular Therapeutics,
Advertisements

Randomized Comparison of Provisional Side Branch Stenting versus a Two-stent Strategy for treatment of True Coronary Bifurcation Lesions Involving a Large.
A multicenter, randomized, prospective DKCRUSH-III study
BBC ONE David Hildick-Smith Sussex Cardiac Centre Brighton, UK on behalf of the BBC ONE Investigators.
Www. Clinical trial results.org  Major Endpoints: Death, MI, stent thrombosis, TLR, TVR, MACE, and CKMB >3x nl  Major Endpoints: Death, MI, stent thrombosis,
Bifurcation coronary stenting: State 0f the Art Mazhar M Khan Consultant Cardiologist Royal Victoria Hospital Belfast, N.Ireland.
BIFURCATION LESIONS Dr. Tahsin.N
Distal Protection: PRIDE, CAPTIVE Symbiot III, AiMI Dr James Cotton MD MRCP Heart and Lung Centre Wolverhampton.
FRACTIONAL FLOW RESERVE versus ANGIOGRAPHY
Randomized Comparison of FFR-guided and Angiography-guided Provisional Stenting for True Coronary Bifurcation Lesions: The DKCRUSH-VI trial Shao-Liang.
2 Year Clinical Outcomes from the Pivotal RESOLUTE US Study Laura Mauri MD, MSc on behalf of the RESOLUTE US Investigators Brigham and Women’s Hospital.
29th ANNUAL SCIENTIFIC SESSIONS – SCA&I
Raising the standard in treating bifurcation lesions GENNARO SARDELLA MD, FACC,FESC O.U. of Interventional Cardiology Dept. of.
DIABETES trial P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín, J Goicolea, F Alfonso, C Bañuelos, J Escaned, R Moreno,
M.Unverdorben; TCT Problem The treatment of stenoses of small coronary arteries (SVD) and of restenoses after stent deployment (ISR) still show.
TITAX AMI Trial Y. Giraud-Sauveur on behalf of P.Karjalainen, MD, PhD : Principal Investigator BCIS 2009 London, UK A Prospective, Randomized Trial Comparing.
CPORT- E Trial Randomized trial comparing outcomes of non-primary PCI at hospitals with and without on-site cardiac surgery.
Two-Year Clinical Outcomes Yan Li MD., PhD. On behalf of FIREMAN Investigators Associated Professor of Department of Cardiology of Xijing Hospital Fourth.
Jie Qian National Heart Center & FuWai Hospitall FFR in Diffuse Multivessel Disease.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
Retrograde approach for the Recanalizaiton of Coronary CTO: Preliminary Experience of Single Centre Lei Ge, Juying Qian, Xuebo Liu, Qin Qing, Junbo Ge.
Upendra Kaul, MD for the TUXEDO INDIA Investigators Paclitaxel Eluting Versus Everolimus Eluting Stents in Patients with Diabetes Mellitus and Coronary.
FRONTIER Registry The Guidant MULTI-LINK FRONTIER ™ Coronary Stent System for the Treatment of Pts with Native De Novo or Restenotic Bifurcation Coronary.
British Bifurcation Coronary Study Objective:To compare the outcome of 2 treatment strategies for bifurcation lesions. Study:Multicenter, randomized trial.
LONG-TERM OUTCOMES OF PERCUTANEOUS CORONARY INTERVENTION FOR UNPROTECTED LEFT MAIN CORONARY ARTERY DISEASE: INITIAL CLINICAL EXPERIENCE. Graidis Ch. 1,
Side Branch Stenting Using Sirolimus-Eluting Stents in Bifurcation Lesions Trial Presented at The American College of Cardiology Scientific Session 2006.
Slow-rate release polymer-based paclitaxel- eluting stent compared with bare stent in patients with single complex coronary lesions TAXUS V Presented at.
Two-Year Outcomes After Everolimus- or Sirolimus- Eluting Stents in Patients With Coronary Artery Disease in the ISAR-TEST 4 Trial Robert A. Byrne, Adnan.
A Prospective, Randomized Trial Evaluating a Paclitaxel-Eluting Balloon in Patients TReated with Endothelial Progenitor Cell CapTuring Stents for De Novo.
Prospective, Randomized Trial of Paclitaxel-Eluting Balloon versus Paclitaxel-Eluting Stent versus Balloon Angioplasty for Treatment of Coronary Restenosis.
Robert A. Byrne, MB MRCPI Deutsches Herzzentrum and 1. Med. Klinik rechts der Isar, Technische Universität Munich, Germany A Polymer-Free Dual Drug-Eluting.
Lianglong Chen MD PhD FACC
Endeavor 4: A Randomized Comparison of a Zotarolimus- Eluting Stent and a Paclitaxel- Eluting Stent in Patients with Coronary Artery Disease Martin B.
Effect of Intravascular Ultrasound- Guided vs. Angiography-Guided Everolimus-Eluting Stent Implantation: the IVUS-XPL Randomized Clinical Trial Myeong-Ki.
ISAR-CABG Objective To compare the efficacy of DES with BMS in a randomized trial powered for clinical events Sample 610 patients with de novo SVG lesions.
Compare Trial 2 year follow-up Peter Smits Maasstad Ziekenhuis Rotterdam The Netherlands.
1 Superiority Of A Simple Stenting Strategy For Coronary Bifurcation Lesions In The Drug-Eluting Stent Era: Evidence From A Meta-Analysis Of 1141 Patients.
Is there any role for intravascular ultrasound in bifurcation lesions? Giuseppe Biondi-Zoccai, MD University of Turin, Turin, Italy.
Cardioprotective Effects of Postconditioning in Patients Treated with Primary PCI Evaluated with Magnetic Resonance Jacob T Lønborg Niels Vejlstrup, Erik.
A Prospective, Randomized Trial of a Paclitaxel coated Balloon vs. uncoated Balloon Angioplasty in Patients with Drug- Eluting Stent Restenosis PEPCAD-DES.
RAVEL 4 YEAR FOLLOW-UP - Cordis Cardiology / Cardialysis – Euro-PCR – Sousa – 24 May 2005 RAVEL A RAndomised, double-blind study with the Sirolimus-eluting.
Ms. Leonardo Roever Coronary Stents. Coronary Artery Disease Leading cause of death in United States for men and women Caused by buildup of plaque in.
Philippe Généreux, MD for the Tryton Bifurcation Trial Investigators Columbia University Medical Center Cardiovascular Research Foundation New York City.
End points in PTCA trials. A successful angioplasty is defined as the reduction of a minimum stenosis diameter to
Final 5 year results from the all-comer COMPARE trial: a prospective randomized comparison between Xience-V and Taxus Liberté TCT 2013 San Francisco Pieter.
(DES)+BVS +DCB for long diffuse LAD disease
Strategy planning in coronary bifurcation stenting
David J. Cohen, M.D., M.Sc. Director of Cardiovascular Research
The Tryton Bifurcation Trial:
TAXUS IV Trial Slow-rate release polymer-based paclitaxel-eluting stent compared with bare stent in patients with single de novo coronary lesions Presented.
FINAL FIVE-YEAR CLINICAL OUTCOMES OF THE NOBORI2 TRIAL
Stenting of Coronary Arteries in Non Stress/Benestent Disease
SKS Technique Clinical Case
Long-term follow-up of the DIABETES I (DIABETes and sirolimus Eluting Stent) trial: P Jiménez-Quevedo, M Sabaté, DJ Angiolillo, JA Gómez-Hospital, R Hernández-Antolín,
BBK II Trial design: Patients undergoing a two-stent approach for a de novo bifurcation lesion were randomized in a 1:1 fashion to either culotte stenting.
American College of Cardiology Presented by Dr. Stephan Windecker
Giuseppe Biondi Zoccai, MD
3-Year Clinical Outcomes From the RESOLUTE US Study
Comparison of Everolimus- and Biolimus-Eluting Coronary Stents With Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-year Outcomes of the EVERBIO.
SIRIUS: A U.S. Multicenter, Randomized, Double-Blind Study of the SIRolImUS-Eluting Stent in De Novo Native Coronary Lesions Presented at TCT 2002.
Bifurcation Disease: Simulation Training Curriculum
Main branch restenosis at 1 year
Incidence and management of restenosis after treatment of unprotected left main disease with drug-eluting stents: 70 restenotic cases from a cohort of.
SMART-STRATEGY Trial design: Patients with a bifurcation coronary lesion were randomized to a conservative strategy (n = 128) vs. an aggressive strategy.
ENDEAVOR III Multicenter Randomized Trial Clinical/MACE Angio/IVUS
Presented at TCT 2006.
Maintenance of Long-Term Clinical Benefit with
ISAR-LEFT MAIN: A Randomized Clinical Trial on Drug-Eluting Stents for Unprotected Left Main Lesions J. Mehilli, MD Deutsches Herzzentrum Technische.
Atlantic Cardiovascular Patient Outcomes Research Team
TYPHOON Trial Trial to Assess the Use of the Cypher Stent in Acute Myocardial Infarction Treated with Balloon Angioplasty (TYPHOON) Trial Presented at.
Presentation transcript:

Treatment of bifurcation lesions is a complex problem Different techniques are commonly used (Y-/T-stenting, „culotte“ technique, „kissing stent“ technique…) Long-time data are sparse Introduction

P= ns Colombo et al, Circulation 2004 Bifurcations: stenting the side branch ?

Stenting of the MB with protection of the side branch with a 2. wire keeps the SB open in 91 % Terkamp et al, ZFK 2002 Bifurcations: protection of the SB using an inserted 2. wire

Stenting of the main branch after covering the side branch using a flow guided concept to treat the side branch (PCI only in case of TIMI flow 0 or 1) is not inferior to a scheduled final kissing balloon PCI with provisional stenting for the SB Study hypothesis

Primary endpoint: –TLR Secondary endpoints: –Restenosis > 50 % –TVR MACE: –Death –Myocardial infarction –Stent thrombosis –CABG Study design I: pre-defined endpoints

110 patients enrolled (September 2004 – December 2006) PES stents were used (Taxus Liberte) Mean FU-duration: 6.1 months Study design II

Inclusion criteria Stable Angina/silent ischemia De-novo true bifurcation lesions (vessel size > 2.25 mm in both branches) Exclusion criteria NSTEMI/STEMI, cardiogenic shock Stenosis of the LM Restenosis/CTO Inclusion/Exclusion criteria

110 consecutive pts with bifurcations - Stenting MB (PES) - „Kissing balloon“-PCI - Provisional stenting SB Group A - Stenting MB (PES) -PCI SB TIMI 0 or 1 Group B (n=54) Scheduled 6 months (n=56) „Complex strategy“„Simple strategy“ Study design: flow chart

Complex strategy Simple strategy p Age Men (%) Diabetics (%) EF (%) Bifurcation LCA (%) Basic data

Complex strategy Simple strategy p Direct stenting MB (%) PCI SB (%) < 0.01 Final kissing balloon-PCI (%) < 0.01 Crossover A B (%) Final TIMI III SB (%) Procedural charakteristics

Complex strategy Simple strategy p Final TIMI III MB (%) Duration X-ray (min) < 0,01 Contrast medium (ml) < 0,01 Troponin I after PCI (24 h) 42,40,6 Procedural charakteristics II

Complex strategy Simple strategy p Re-PCI MB (%) (Re)-PCI SB (%) Stent thrombosis (%) CABG related to lesion (%) TLR (sum, %) PCI target vessel, non target lesion (%) TVR (sum, %) Cardiac death (%) ALL MACE (%) Follow-up 6 months

Complex strategy Simple strategy p Binary restenosis MB (%) Late lumen loss MB (mm) Follow-up data: QCA (In- Segment)

A simple strategy using PES with only provisional SB-PCI according to the TIMI flow of the SB is not inferior to a more complex strategy with mandatory SB-PCI Conclusions I: treatment of bifurcation lesions

MACE rates are nearly identical for both strategies Comparing the duration of radioscopy + the amount of contrast medium benefits were revealed for the simple strategy The more simpler strategy may be the more better strategy… Conclusions II: treatment of bifurcation lesions

Thank you very much for your attention